PDE5A and Duchenne muscular dystrophy: This suggests that PDE5 inhibitors could show less decline in ambulation in younger and less disabled DMD boys [6], and in addition, it also suggests that enhancement of cGMP with PDE5 inhibitors was beneficial but still under the critical threshold to show clinical benefit.